Akamis Bio Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$60M
- Investors
-
25
Akamis Bio General Information
Description
Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobiology treatments for solid tumors using the proprietary intravenously administered T-SIGn virus platform, enabling patients to get proper treatment who are suffering from cancer.
Contact Information
Website
www.akamisbio.comCorporate Office
- 4-10 The Quadrant, Abingdon Science Park
- Barton Lane, Oxfordshire
- Abingdon OX14 3YS
- England, United Kingdom
Corporate Office
- 4-10 The Quadrant, Abingdon Science Park
- Barton Lane, Oxfordshire
- Abingdon OX14 3YS
- England, United Kingdom
Akamis Bio Timeline
Akamis Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series A) | 17-Dec-2024 | $60M | Completed | Clinical Trials - Phase 1 | ||
| 13. Later Stage VC | 05-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 12. Secondary Transaction - Private | 27-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 11. Later Stage VC | 16-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 10. Later Stage VC (Series C) | 19-May-2015 | Completed | Pre-Clinical Trials | |||
| 9. Grant | 07-Oct-2013 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 31-Oct-2012 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series B) | 16-Oct-2012 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 12-Sep-2011 | $2.92M | $10.3M | Completed | Pre-Clinical Trials | |
| 5. Early Stage VC | 15-Dec-2010 | $5.68M | $10.3M | Completed | Pre-Clinical Trials |
Akamis Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B-2 Preferred | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A | 981 | $0.012138 | $53.41 | $53.41 | 1x | $53.41 | 0.06% | |
| Series A | 126,176 | $0.012138 | $66.76 | $66.76 | 1x | $66.76 | 7.79% |
Akamis Bio Comparisons
Industry
Financing
Details
Akamis Bio Competitors (55)
One of Akamis Bio’s 55 competitors is Replimune, a Formerly VC-backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Replimune | Formerly VC-backed | Woburn, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Macrogenics | Formerly VC-backed | Rockville, MD |
Akamis Bio Patents
Akamis Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117753-A1 | Viral vectors for expression of synthetic cancer antigens and chemokine and related methods and uses | Pending | 27-Nov-2024 | ||
| AU-2025220163-A1 | Engineered cancer antigens and related methods and uses | Pending | 09-Feb-2024 | ||
| WO-2025171383-A2 | Engineered cancer antigens and related methods and uses | Pending | 09-Feb-2024 | ||
| WO-2025171383-A3 | Engineered cancer antigens and related methods and uses | Pending | 09-Feb-2024 | ||
| GB-202211075-D0 | Virus | Inactive | 28-Jul-2022 |
Akamis Bio Signals
Akamis Bio Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lundbeckfonden | Limited Partner | Minority | ||
| Parker Institute for Cancer Immunotherapy | Corporation | |||
| Westlake Village BioPartners | Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Rosetta Capital (UK) | Venture Capital | Minority |
Akamis Bio FAQs
-
When was Akamis Bio founded?
Akamis Bio was founded in 2006.
-
Where is Akamis Bio headquartered?
Akamis Bio is headquartered in Abingdon, United Kingdom.
-
What is the size of Akamis Bio?
Akamis Bio has 34 total employees.
-
What industry is Akamis Bio in?
Akamis Bio’s primary industry is Drug Discovery.
-
Is Akamis Bio a private or public company?
Akamis Bio is a Private company.
-
What is Akamis Bio’s current revenue?
The current revenue for Akamis Bio is .
-
How much funding has Akamis Bio raised over time?
Akamis Bio has raised $185M.
-
Who are Akamis Bio’s investors?
Lundbeckfonden, Parker Institute for Cancer Immunotherapy, Westlake Village BioPartners, Bristol-Myers Squibb, and Rosetta Capital (UK) are 5 of 25 investors who have invested in Akamis Bio.
-
Who are Akamis Bio’s competitors?
Replimune, Celldex, Oncorus, Rein Therapeutics, and Macrogenics are some of the 55 competitors of Akamis Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process